Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer oral anti-diabetic agents which have been approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes mellitus (T2DM). In this analysis, we aimed to systematically compare the cardiovascular outcomes associated with DPP-4 inhibitors versus non-DPP-4 inhibitor users. METHODS: All English publications that compared the use of DPP-4 inhibitors and that reported cardiovascular outcomes in patients with T2DM were searched using specific terms. Studies were included if they satisfied the following inclusion criteria: They were randomized trials or observation cohorts/registries comparing DPP-4 inhibitors use in patients with T2DM; The studies included a large sample size of participants; And they reported cardiovascular outcomes as their main endpoints. RevMan 5.3 was used to analyze the data, and odds ratios (OR) with 95% confidence intervals (CI) were used to represent the results. RESULTS: A total number of 157,478 participants with T2DM were included. Seventy-six thousand and twenty six patients were assigned to the DPP-4 inhibitor group whereas 81,452 patients were assigned to the control group. Results of the current analysis showed that during a mean follow-up time period ranging from 52 to 152 weeks, the primary endpoint (cardiovascular death/non-fatal myocardial infarction (MI)/non-fatal stroke) was not significantly different in the treatment of T2DM patients with versus without DPP-4 inhibitors (OR: 0.95, 95% CI: 0.86-1.04; P = 0.26). Cardiovascular death (OR: 1.00, 95% CI: 0.90-1.10; P = 0.93), stroke (OR: 1.03, 95% CI: 0.89-1.18; P = 0.72), MI (OR: 0.97, 95% CI: 0.88-1.07; P = 0.59), all-cause mortality (OR: 0.84, 95% CI: 0.59-1.18; P = 0.31), hospitalization for cardiovascular complications (OR: 1.02, 95% CI: 0.96-1.09; P = 0.45) and hospitalization specifically for heart failure (OR: 1.05, 95% CI: 0.90-1.23; P = 0.55) were also similarly manifested in both groups. CONCLUSION: The current analysis showed that treatment with DPP-4 inhibitors did not significantly increase cardiovascular outcomes in these patients with T2DM indicating that those drugs might be safe to use in terms of cardiovascular events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent observational studies, CVOTs, and meta-analyses have not shown an excess heart failure risk with DPP4 inhibitors.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [217]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 1×
“…patients assigned to control group (n) Gantz2017 [7] RCT 2012–2017 2092 2100 Green2015 [8] RCT 2008–2015 7332 7339 Park2015 [9] OS 2007–2011 1866 5179 Scirica2013 [10] RCT 2010–2011 8280 8212 Shih2016 [11] OS 2009–2013 53,208 53,208 Wang2015 [12] OS 2009–2011 547 2735 White2013 [13] RCT…”
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 2×
“When study Green2015 was excluded, results for primary endpoint (OR: 0.93, 95% CI: 0.84–1.02; P = 0.14), cardiovascular death (OR: 0.95, 95% CI: 0.83–1.08; P = 0.42), stroke (OR: 1.07, 95% CI: 0.89–1.28; P = 0.48), MI (OR: 0.99, 95% CI: 0.88–1.12; P = 0.86), hospitalization for cardiovascular…”
InfluentialAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“…[9] OS 2007–2011 1866 5179 Scirica2013 [10] RCT 2010–2011 8280 8212 Shih2016 [11] OS 2009–2013 53,208 53,208 Wang2015 [12] OS 2009–2011 547 2735 White2013 [13] RCT 2009–2013 2701 2679 Total no of patients (n) 76,026 81,452 Abbreviations: RCT Randomized controlled trials, OS…”
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience
Hiatt, W. R., Kaul, S., & Smith, R. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1309610 · Cited by 204
Zhong, J., Maiseyeu, A., Davis, S. N., & Rajagopalan, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.305665 · Cited by 189 · cited 1×
“Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer anti-diabetic agents which have shown to well maintain blood glucose level over the long-term (decent glycated hemoglobin [HbA1c]), and were not associated with hypoglycemia or weight gain in comparison to other similar drugs [4].”
BackgroundGantz, I., Chen, M., Suryawanshi, S., Ntabadde, C., Shah, S., O’Neill, E. A., Engel, S. S., Kaufman, K. D., & Lai, E. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0593-8 · Cited by 108 · cited 2×
“…of study Time period of patients’ enrollment Total no of patients assigned to DPP-4 inhibitors (n) Total no of patients assigned to control group (n) Gantz2017 [7] RCT 2012–2017 2092 2100 Green2015 [8] RCT 2008–2015 7332 7339 Park2015 [9] OS 2007–2011 1866 5179 Scirica2013 [10] RCT 2010–2011 8280…”
BackgroundInfluential
Cited by
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
C-reactive protein: a target for therapy to reduce inflammation
Rizo-Téllez, S. A., Sekheri, M., & Filep, J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237729 · Cited by 182
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Patoulias, D. I., Boulmpou, A., Teperikidis, E., Katsimardou, A., Siskos, F., Doumas, M., Papadopoulos, C. E., & Vassilikos, V. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i10.585 · Cited by 70
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
Metadata
- Authors
- Liu, D., Jin, B., Chen, W., & Yun, P.
- Affiliations
- First People's Hospital of Jingzhou (CN)
- Corresponding author
- Liu, Dan
- Venue
- BMC Pharmacology and Toxicology
- Published
- 2019-03-04
- Volume
- 20
- Issue
- 1
- Pages
- 15-15
- ISSN
- 2050-6511 (ISSN-L)
- PMC
- PMC6399924
- OpenAlex
- W2918566284
- Cited by
- 56
- References
- 16
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 7 · 2022: 6 · 2021: 11 · 2020: 8 · 2019: 1
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- BMC Pharmacology and Toxicology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- DPP-4 inhibitors, type 2 diabetes, cardiovascular outcomes, cardiovascular mortality, myocardial infarction, stroke, all-cause mortality, cardiovascular hospitalization, oral antidiabetic drugs, comparative effectiveness, cardiovascular safety, glycemic control, HbA1c, LDL cholesterol, blood pressure, body mass index, cardiovascular risk factors, cardiovascular risk stratification
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Odds Ratio, Randomized Controlled Trials as Topic, Dipeptidyl-Peptidase IV Inhibitors, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s40360-019-0293-y
- The paper
- Liu, D., Jin, B., Chen, W., & Yun, P. (2019). Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-019-0293-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.